



Company Announcement

Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022

- *Management to host a Capital Markets Day on May 12, 2022 at 2.00-4.00 p.m. CET / 8.00-10.00 a.m. ET*
- *The event is a live, virtual event with the possibility for physical participation. The event may be followed via a live audio webcast with access to presentation slides from the Company's website or by conference call*
- *Highlights to be covered will include an overview of our pipeline; a deep dive into the Company's unique technology projects; and its capital markets initiative with respect to a potential transfer of the listing of the Company's shares from Euronext Growth Oslo to the main market of Oslo Stock Exchange*

Oslo, Norway, May 6, 2022 – Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, invites to a Capital Markets Day for analysts and investors in Oslo, Norway, on May 12, from 2.00-4.00 p.m. CET / 8.00-10.00 a.m. ET. The event will be hosted both with the possibility for physical attendance and as a live webcast from Nykode's facilities in Oslo, Norway, and will take place in English.

The Capital Markets Day will feature Nykode's Executive Management Team who will provide updates on Nykode's business, pipeline, and innovations. All sessions are webcasted live, and a replay will be made available on the investor section of nykode.com. The presentation material from the Capital Markets Day will also be available on the day from 8.00 a.m. CET on the investor section of nykode.com.



Topics of the Capital Markets Day will include:

- Nykode's business status and journey
- Pipeline update - Overview of Nykode's product candidate pipeline and clinical experience
- Research update - Deep dive into Nykode's research and the ongoing technology projects
- Capital market strategy update, including potential uplisting to the main market of Oslo Stock Exchange (Oslo Børs)

Physical attendance requires registration. To register for the physical event, please send an email to ctran@nykode.com before May 11 at 3.00 p.m. CET.

Event details

Date and time: May 12, 2022 at 2.00-4.00 p.m. CET / 8.00-10.00 a.m. ET

Location: Forum Auditorium, Oslo Science Park, Gaustadalléen 21, 0349 Oslo, Norway

Webcast and replay: at <https://nykode.com/investors/financial-reports-and-presentations>.

Presentation material: at <https://nykode.com/investors/financial-reports-and-presentations>.

Conference call dial in numbers and pin code:

PIN Code for all countries: 755176

US: +1 646-787-0157 UK: +44-203-7696819 CH: +41-22-5017540

DE: +49-30-21789327 FR: +33-1-81221259 BE: +32-2-6810135

NL: +31-20-3690737 LU: +352-20-301626 DK: +45 78768490

SE: +46-8-1241-0952 NO: +47-21-956342

Registration for physical attendance: Before May 11 at 3.00 p.m CET by email: ctran@nykode.com

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.



Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.

The Company's partnerships include Roche and Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

Contact for Nykode Therapeutics AS:

CEO Michael Engsig
Nykode Therapeutics AS
IR@nykode.com

Nykode Therapeutics AS

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.